Urothelial Carcinoma Training & Resources

Prescribing Information [External link]

KEYTRUDA® (pembrolizumab) + enfortumab vedotin▼ in unresectable or metastatic urothelial carcinoma (u/mUC)

Expert on Demand Programme

KEYNOTE-A39/EV-302 Presentation

Expert Considerations Guide

Early Identification of Adverse Events Coaching Guide

KEYTRUDA, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.¹

Please refer to the Summary of Product Characteristics and Risk Minimisation Materials for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

Reference

1. KEYTRUDA Summary of Product Characteristics.